Newborn blood-spot screening (heel prick) — what it tests and why

The question

What does the heel-prick test screen for, how accurate is it, and what happens if the result comes back positive?

Short answer

Around day 5, a midwife pricks your baby's heel and collects a few drops of blood to screen for nine rare but serious conditions — including sickle cell disease, cystic fibrosis, congenital hypothyroidism, and PKU — where catching the condition early allows treatment to start before symptoms appear. About 97 in 100 babies in England are screened [2]. A "screen positive" is not a diagnosis: it means further testing is needed, and many screen-positive babies turn out not to have the condition [1][3].

What the strongest evidence says

The nine conditions

The UK programme screens for nine conditions where early detection changes the course: sickle cell disease, cystic fibrosis, congenital hypothyroidism, phenylketonuria (PKU), MCADD, maple syrup urine disease, isovaleric acidaemia, glutaric aciduria type 1, and pyridoxine-unresponsive homocystinuria [1]. SCID (severe combined immunodeficiency) is being evaluated in England but is not currently in the core nine [8]. The sample is usually taken on day 5 [1].

What a "positive" triggers

A screen-positive result is not a diagnosis — it means your baby is referred to specialists for confirmatory testing, fast [1]. How fast depends on urgency [4]:

In 2017/18, 100% of babies screening positive for MCADD, maple syrup urine disease, isovaleric acidaemia, and glutaric aciduria type 1 were clinically referred within 3 working days of the lab receiving the sample [3].

How well the programme works — and what it can't tell you

• Coverage is high. Reported coverage in England was 97.3% in 2023/24 [2] — nearly every baby is offered and receives the test.
• Screen positives are counted, diagnoses aren't (in public reports). In 2017/18 the UK reported 329 screen positives for cystic fibrosis, 690 for congenital hypothyroidism, 255 for sickle cell disease, 113 for PKU, 67 for MCADD, and 38 for the other four metabolic conditions — with the explicit note that "not all will have been confirmed to have the disorder" [3]. Because published reports count screen positives rather than confirmed diagnoses, you cannot compute a positive predictive value from them.
• There is no single accuracy number. The programme itself states that "screening is not 100% accurate" [1]. How often a positive screen turns out to be real depends on the condition and the testing algorithm — so anyone quoting one overall "accuracy" figure for the heel prick is making it up.
• Uncertain and carrier results are part of the design. Some screens return inconclusive results — for example "CF screen positive, inconclusive diagnosis" (CFSPID), where the baby is well, does not have a cystic fibrosis diagnosis, and most children remain well, though a small number may later be diagnosed [6]. The screen can also reveal that a baby is a carrier for sickle cell or cystic fibrosis, which has implications for family counselling [7].
• Results reach you by 6 weeks. Parents should receive normal results by 6 weeks — and the programme stresses that "no news is good news" is not the policy: if you haven't heard, chase it up [1].

What it doesn't do

• It doesn't diagnose — it flags. Only confirmatory testing diagnoses [1].
• It doesn't test for everything. Nine conditions, not a general health check — a normal result doesn't mean nothing can ever be wrong [1].
• It isn't perfect. False positives cause real distress [5], and false negatives are possible — which is why ongoing health concerns should always go to your GP or health visitor regardless of the result [1].

What it means for the parents

The heel prick is a rare moment where the medical system is firmly on your side — a simple, nearly universal test looking for things you'd want to know about. But the psychology of it deserves honesty:

• A positive result is frightening, and the fear often outlasts the all-clear. A 2024 scoping review found mixed evidence: some parents had persistent anxiety after a false positive, while other cohorts showed low long-term anxiety [5]. What seemed to matter most was how the result was communicated and whether counselling was available — not just the result itself [5].
• The waiting is the hard part. Between a positive screen and confirmatory testing, you can spend days or weeks not knowing whether your baby is ill. Knowing in advance that a screen positive is a flag for more testing, not a diagnosis, doesn't remove the fear — but it does give you the right mental frame [1][4].
• Carrier findings raise family questions. Learning your baby carries a sickle cell or CF gene variant can prompt questions about your own carrier status and future pregnancies — the programme's carrier pathways include family counselling for exactly this reason [7]. This is useful information, but it's worth knowing it can arrive uninvited.
• Day 5 is a lot. The heel prick lands in the same stretch as night-time cluster feeding, the emotional crash of the early days, and a parade of midwife visits. It's a difficult moment to absorb complex information — knowing the test is coming, and what it can and can't say, is the best preparation available.
• The test is offered, not compulsory. Almost everyone accepts (97.3% coverage [2]), and the programme exists because for these nine conditions, early detection allows treatment to start before symptoms appear [1] — but it's still your decision, and you can ask questions first.
• The heel prick itself is minor; the information isn't. A few drops of blood and it's over in minutes [1] — but the results can reshape your family's medical picture (carrier status, inconclusive labels like CFSPID [6]). Going in knowing the test can return uncertain answers, not just yes/no, makes those answers easier to hold.
• Have a sentence ready for family. If a screen positive lands, relatives will ask questions you can't answer yet. "The screening flagged something that needs a second test; the baby is well" is enough until you know more — it protects you from managing other people's anxiety on top of your own.
• Ask about the wider family. Carrier findings can be relevant for siblings and future pregnancies — which is exactly why the programme's carrier pathways include family counselling [7]. If a carrier result lands, take up the counselling offer rather than Googling alone.

What remains uncertain

• Condition-by-condition accuracy. Published programme data report screen positives, not confirmed diagnoses [3], so positive predictive values per condition are not available in one place. Part of the reason is structural: confirming every screen positive takes weeks, and the programme reports operational data (how many were flagged, how fast they were referred) rather than diagnostic-accuracy studies. The evidence suggests the screen is a good net with some bycatch — it does not tell us exactly how much.
• Long-term parental anxiety after false positives: evidence is mixed and mostly short-term [5].
• The benefit of early detection is the programme's founding rationale (assessed condition-by-condition by the UK NSC), but this topic did not re-verify each condition's treatment evidence study-by-study.

Benefits and risks in absolute terms

Benefits:

• Around 97 in 100 babies in England are screened [2]; the test detects rare conditions early enough for treatment to start before symptoms — for example, thyroid hormone replacement for congenital hypothyroidism or dietary management for PKU and MCADD [1].
• Screen-positive babies with the most time-critical conditions are referred to specialists within 3 working days [3].

Risks and downsides:

• False positives and inconclusive results: they happen — 690 babies screened positive for congenital hypothyroidism in 2017/18, for instance, not all of whom had the condition [3]. Each one means days of worry and extra tests for a family whose baby is fine. The programme accepts that bycatch because the conditions flagged "urgent, at immediate risk" need treatment fast — a missed case carries serious risk [4].
• Carrier and inconclusive findings (e.g. CFSPID) create uncertainty and follow-up without a diagnosis [6][7].
• Missed cases: screening is not 100% accurate — a normal result does not guarantee a condition is absent, so ongoing concerns about your baby's health should still go to your GP or health visitor [1].

Practical considerations

• The heel prick is usually done on day 5 by your midwife, at home or in hospital — a small prick to the heel, a few drops of blood spotted onto a card, and it's done in minutes [1].
• It helps to know before day 5 what the test looks for. The nine conditions are rare; the point of knowing the list is that a "positive" for one of them lands differently when you've heard the name before.
• You should receive results (or a "normal" letter) by 6 weeks. If you haven't heard anything by then, contact your health visitor — do not assume silence means all clear [1].
• If your baby needs a repeat sample (about 2.5% of samples in England needed an avoidable repeat in 2017/18 [3]), results usually follow within 14 days; parents are told to expect anxiety and to ask for the other results to be shared as soon as they're ready [1].
• A screen-positive result triggers a specialist appointment, not a diagnosis — ask what the next test is, when it happens, and who to call with questions in the meantime [4].
• Keep the result letter with your baby's red book (personal child health record) — the programme asks health visitors to record results there, and future clinicians may ask [1].
• Write down any questions before the day-5 visit — you won't remember them in the moment.
• If a screen-positive call comes, note the caller's name and direct number before anything else; you'll want it for every subsequent conversation.
• If your baby was born prematurely, expect a repeat sample for congenital hypothyroidism — the programme has a specific preterm repeat pathway [1].
• If you move house in the first weeks, tell your new GP and health visitor promptly — the programme tracks "movers in" as a separate group, and results can go astray while records transfer [1].

When to talk to your doctor, midwife, or pediatrician

Contact your health visitor or GP if: you haven't received results by 6 weeks; you've been told of a screen-positive result and don't understand what happens next — it's okay to ask the caller to slow down, spell the condition name, and explain what the next test involves [4]; you're struggling with anxiety while waiting for confirmatory tests; or you have any concern about your baby's health regardless of a normal screening result — screening doesn't catch everything [1].

References

1. GOV.UK. Newborn blood spot screening: supporting information (programme standards). https://www.gov.uk/government/publications/standards-for-nhs-newborn-blood-spot-screening/newborn-blood-spot-screening-supporting-information — D (official programme documentation)
2. NHS England. Accountability statement: public health functions (Section 7A) agreement 2023 to 2024. https://assets.publishing.service.gov.uk/media/6867f642a08d3a3ca3b6778e/nhs-england-accountability-statement-public-health-functions-s7a-agreement-2023-to-2024.pdf — C (administrative coverage data)
3. Public Health England. Newborn blood spot screening: data collection and performance analysis report, UK 2017 to 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/946076/Newborn_blood_spot_screening_Data_Collection_and_Performance_Analysis_Report_2017_to_2018_v4.pdf — C (programme surveillance; screen positives, not confirmed diagnoses)
4. Chudleigh J et al. Rethinking Strategies for Positive Newborn Screening Result (NBS+) Delivery (ReSPoND): a process evaluation. https://pmc.ncbi.nlm.nih.gov/articles/PMC6724281/ — C (qualitative/service design)
5. Scoping review of psychosocial outcomes after newborn screening false positives. Children. 2024;11(5):507. https://www.mdpi.com/2227-9067/11/5/507/xml — C (heterogeneous studies, no pooled estimate)
6. Sheffield Children's NHS Foundation Trust. Inconclusive diagnosis after a positive screening for cystic fibrosis (CFSPID). https://library.sheffieldchildrens.nhs.uk/inconclusive-diagnosis-after-a-positive-screening-for-cystic-fibrosis/ — D (clinical resource)
7. GOV.UK. Handbook for sickle cell and thalassaemia screening; NHS CF carrier results pathway. https://www.gov.uk/government/publications/handbook-for-sickle-cell-and-thalassaemia-screening/newborn-screening — D (programme documentation)
8. UK National Screening Committee. UK NSC consults on extending the in-service evaluation of screening for SCID. 2025-08-07. https://nationalscreening.blog.gov.uk/2025/08/07/uk-nsc-consults-on-extending-the-in-service-evaluation-of-screening-for-scid/ — D (policy status)

Changelog

• 2026-09-08: Topic created (draft). Awaiting independent review. (Superseded 2026-09-09: author-review model, no external review before v1.)
• 2026-09-09: Full author review (v1 author-review model; reviewer Guille, executed by AI agent under his explicit delegation of 2026-09-09). Nine-condition list verified current against GOV.UK programme standards (SCID still in evaluation, UK NSC evidence summary March 2026 — re-check at next review). "No single accuracy number" stance kept as a deliberate editorial decision. All eight author flags resolved; direct links added to all references. Verdict: approve.